article thumbnail

AI Regulations for Financial Services: Federal Reserve

Perficient: Drug Development

Artificial intelligence (AI) is poised to affect every aspect of the world economy and play a significant role in the global financial system, leading financial regulators around the world to take various steps to address the impact of AI on their areas of responsibility. Criteria for assessment.

article thumbnail

FDA holds the line on remanufacturing definitions in newly finalized guidance

Agency IQ

The new guidance maintains the agency’s existing definitions of remanufacturing and servicing, but adds a new section that provide a high level overview of the medical device regulations – primarily for those “less familiar.”

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Fourth Circuit Upholds CMS’ Definition of “Line-Extension Drug” and “New Formulation”

FDA Law Blog: Biosimilars

Gaulkin — On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP).

Drugs 57
article thumbnail

EPA releases final PFAS drinking water regulations – with five-year compliance timeline

Agency IQ

BY WALKER LIVINGSTON, ESQ The EPA has released its much-awaited National Primary Drinking Water Regulation for six different PFAS. There are a wide variety of definitions for PFAS and consistent debate on which definition is most applicable. Fill out the form to read the full article.

article thumbnail

CMS Definition of “New Formulation” Upheld in Federal Court

FDA Law Blog: Biosimilars

Kirschenbaum — On March 31, the Federal District Court for the District of Maryland upheld CMS’s definition of a “new formulation” under the Medicaid Drug Rebate Program (MDRP). Examples in the regulation include extended-release formulations, new strengths, dosage forms, routes of administration, ingredients, and combinations.

Drugs 57
article thumbnail

Article FDA Thank You FDA holds the line on remanufacturing definitions in newly finalized guidance

Agency IQ

FDA holds the line on remanufacturing definitions in newly finalized guidance Almost three years after the initial draft, the FDA has now finalized guidance describing the differences between medical device “servicing” and “remanufacturing” and each activity’s quality system implications. That draft guidance came out in 2021.

FDA 40
article thumbnail

Analysis Chemical: PFAS regulation in California (late 2023 edition)

Agency IQ

PFAS regulation in California (late 2023 edition) California consistently maintains its status as both one of the most important economies in the world as well as one of the most regulated states in the United States. A quick background on PFAS Per- and polyfluoroalkyl substances (PFAS) are a wide class of synthetic organic chemicals.